Assessing the robustness of clinical trials by estimating Jadad's score using artificial intelligence approaches.

Journal: Computers in biology and medicine
Published Date: Jul 19, 2022

Abstract

BACKGROUND: Clinical trials are essential in medical science and are currently the most robust strategy for evaluating the effectiveness of a treatment. However, some of these studies are less reliable than others due to flaws in their design. Assessing the robustness of a clinical trial can be a very complex and time-consuming task, with factors such as randomization, masking and the description of withdrawals needing to be considered.

Authors

  • Tiphaine Casy
    LTSI MediCIS Team, UMR 1099, University of Rennes 1, Inserm, Rennes, France.
  • Alexis Grasseau
    MICMAC, UMR 1236, University of Rennes 1, Inserm, Rennes, France.
  • Amandine Charras
    Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
  • Bénédicte Rouvière
    b Lymphocytes B et Autoimmunité Université de Brest, Inserm, CHU Brest, LabEx IGO , Brest , France.
  • Jacques-Olivier Pers
    c Internal Medicine Unit, CHU , Brest , France.
  • Nathan Foulquier
    LBAI, UMR1227, INSERM, University of Western Brittany, Brest France and Centre Hospitalier Universitaire de Brest, Brest, France.
  • Alain Saraux
    Université de Bretagne Occidentale (Univ Brest), Department of Rheumatology; Pôle PHARES, CHU Brest, INSERM (U1227), LabEx IGO, Brest, France 29200 Brest, France.

Keywords

External Resources

Popular Topics
Recent Journals